8-K: Bio-Path Holdings Announces 2025 Clinical and Operational Update, Highlighting Progress in Oncology and Expansion into Obesity Treatment

Bio-Path Holdings provides a clinical and operational update for 2025, emphasizing advancements in its oncology programs and the exploration of BP1001-A for treating obesity in Type 2 Diabetes.

Summary

• Bio-Path Holdings is advancing multiple clinical programs, including a Phase 2 trial and two Phase 1/1b trials.
• The company is developing a molecular biomarker package for its Phase 2 AML clinical trial to identify patients more likely to respond to prexigebersen treatment.
• Bio-Path expects to utilize these biomarkers in 2025 and evaluate prexigebersen for obesity treatment.
• BP1001-A is in preclinical development for treating obesity in Type 2 Diabetes, with a potential IND submission to the FDA later in the year.
• The Phase 2 AML trial includes three cohorts, each potentially approvable by the FDA as a new indication.
• The first two cohorts involve a triple combination of prexigebersen, decitabine, and venetoclax for untreated and relapsed/refractory AML patients.
• The third cohort treats relapsed/refractory AML patients resistant to venetoclax with prexigebersen and decitabine.
• Median survival for older AML patients unable to receive intensive chemotherapy is only 5 to 10 months.
• Bio-Path expects to complete Cohort 2 and conduct an interim analysis for Cohort 3 in 2025.
• A Phase 1/1b trial of BP1001-A in advanced solid tumors is ongoing, with the first patient in the second dose cohort showing a positive response.
• This patient with gynecologic cancer experienced a 15% reduction in her primary tumor after nine cycles and continues to do well after ten months on the study.
• Completion of the second and third dosing cohorts for the solid tumor trial is expected in 2025.
• A Phase 1/1b trial for BP1002 in relapsed/refractory AML patients is ongoing, with the third dosing cohort enrollment closing faster than expected.
• Preclinical studies confirmed the effectiveness of BP1001-A in affecting insulin signaling and its potential efficacy as a therapeutic treatment for obese patients who have Type 2 diabetes.
• Bio-Path expects to complete preclinical testing and file an IND for this indication in 2025.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with advancements in clinical programs and expansion into new therapeutic areas. However, it also acknowledges the risks and uncertainties inherent in drug development, resulting in a moderately positive sentiment.

Positives

• Positive data generated in oncology programs.
• Addition of a new application for BP1001-A in the treatment of obesity for Type 2 Diabetes.
• Development of a molecular biomarker package to improve patient selection for prexigebersen treatment.
• Positive response observed in a patient with advanced solid tumors treated with BP1001-A.
• Faster than expected enrollment in the third dosing cohort for the Phase 1/1b trial of BP1002 in relapsed/refractory AML.

Negatives

• Outcomes for older AML patients who are unable to receive intensive chemotherapy remain suboptimal with a median survival of only 5 to 10 months.

Risks

• The company's ability to raise needed additional capital on a timely basis in order for it to continue its operations.
• Success in the clinical development of its technologies.
• The timing of enrollment and release of data in such clinical studies.
• The accuracy of such data.
• Limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials.
• The maintenance of intellectual property rights.
• That patents relating to existing or future patent applications will be issued or that any issued patents will provide meaningful protection of our drug candidates.
• The impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith.

Future Outlook

Bio-Path anticipates several milestones in 2025, including completing Cohort 2 and an interim analysis for Cohort 3 in the Phase 2 AML trial, completing the second and third dosing cohorts for the Phase 1/1b solid tumor trial, and potentially filing an IND for BP1001-A in obesity treatment for Type 2 Diabetes.

Management Comments

• Peter H. Nielsen, President and Chief Executive Officer of Bio-Path, stated that the work conducted in 2024 has led to an exciting 2025, building off positive data in oncology and the addition of a new application for BP1001-A in obesity treatment for Type 2 Diabetes.
• Nielsen emphasized the importance of developing effective new medicines for patients with few treatment options and the potential of the DNAbilize platform to make a difference in patients' lives.

Industry Context

The announcement reflects the broader industry trend of leveraging biomarkers to enhance cancer drug development and exploring new therapeutic applications for existing drug candidates. The expansion into obesity treatment aligns with the growing market for diabetes and weight management therapies.

Comparison to Industry Standards

• The development of molecular biomarker packages aligns with industry best practices in oncology drug development, similar to companies like Roche and Novartis who use companion diagnostics to improve patient selection and treatment outcomes.
• The focus on relapsed/refractory AML patients, including those resistant to venetoclax, addresses a significant unmet need, comparable to efforts by companies like AbbVie and Agios to develop therapies for this patient population.
• The exploration of BP1001-A for obesity in Type 2 Diabetes positions Bio-Path in a competitive market alongside companies like Novo Nordisk and Eli Lilly, who are developing and marketing GLP-1 receptor agonists for weight loss and glucose control.

Stakeholder Impact

• Shareholders may see potential for increased value due to clinical advancements and new therapeutic applications.
• Patients with AML, solid tumors, and Type 2 Diabetes may benefit from new treatment options.
• Employees may experience increased workload and opportunities for professional development.
• The company's success could lead to increased demand for suppliers and collaborators.

Next Steps

• Complete preclinical testing and file an IND for BP1001-A in obesity treatment for Type 2 Diabetes.
• Complete Cohort 2 and conduct an interim analysis for Cohort 3 in the Phase 2 AML trial.
• Complete the second and third dosing cohorts for the Phase 1/1b solid tumor trial.
• Initiate Phase 1b studies in combination with paclitaxel in patients with recurrent ovarian or endometrial tumors.
• Initiate Phase 1b studies in combination with gemcitabine in Stage 4 pancreatic cancer and combination therapy in breast cancer.

Key Dates